title: Sunitinib-induced hemoglobin changes are related to the dosing schedule.
authors.forename: Astrid A M
authors.initials: AA
authors.lastname: van der Veldt
authors.forename: Epie
authors.initials: E
authors.lastname: Boven
authors.forename: Laura
authors.initials: L
authors.lastname: Vroling
authors.forename: Henk J
authors.initials: HJ
authors.lastname: Broxterman
authors.forename: Alfons J M
authors.initials: AJ
authors.lastname: van den Eertwegh
authors.forename: John G
authors.initials: JG
authors.lastname: Haanen
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004334:Drug Administration Schedule; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects*; D011086:Polycythemia / Q000139:chemically induced; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects*; D000077210:Sunitinib; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors / Q000502:physiology
chemical_list: D000970:Antineoplastic Agents; D006454:Hemoglobins; D007211:Indoles; D011758:Pyrroles; D040301:Vascular Endothelial Growth Factor Receptor-2; D000077210:Sunitinib